HUTCHMED Competitors
| HCM Stock | USD 14.56 0.44 2.93% |
HUTCHMED DRC vs Kiniksa Pharmaceuticals Correlation
Very good diversification
The correlation between HUTCHMED DRC and KNSA is -0.25 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding HUTCHMED DRC and KNSA in the same portfolio, assuming nothing else is changed.
Moving against HUTCHMED Stock
| 0.64 | URBN | Urban Outfitters | PairCorr |
| 0.61 | EYPT | Eyepoint Pharmaceuticals | PairCorr |
| 0.54 | SEPN | Septerna Common Stock | PairCorr |
| 0.34 | TLKMF | Telkom Indonesia Tbk | PairCorr |
| 0.33 | PTITF | PT Indosat Tbk Earnings Call This Week | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of HUTCHMED DRC's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
HUTCHMED DRC Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between HUTCHMED DRC and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of HUTCHMED and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of HUTCHMED DRC does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between HUTCHMED Stock performing well and HUTCHMED DRC Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze HUTCHMED DRC's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BHC | 2.49 | (0.10) | 0.00 | (0.06) | 0.00 | 6.20 | 22.08 | |||
| PRGO | 1.97 | (0.61) | 0.00 | (0.54) | 0.00 | 3.42 | 25.71 | |||
| IDYA | 1.97 | 0.02 | 0.01 | 0.07 | 2.14 | 4.86 | 10.56 | |||
| SUPN | 1.54 | (0.09) | 0.00 | 0.67 | 0.00 | 3.24 | 22.07 | |||
| CPRX | 1.42 | 0.21 | 0.12 | 0.33 | 1.54 | 3.00 | 10.89 | |||
| SRRK | 2.90 | 0.72 | 0.25 | 0.99 | 2.40 | 5.92 | 31.68 | |||
| ADPT | 3.06 | 0.20 | 0.05 | 0.35 | 3.83 | 9.94 | 29.55 | |||
| MLYS | 2.39 | (0.42) | 0.00 | (0.28) | 0.00 | 5.87 | 24.81 | |||
| CDTX | 4.25 | 1.60 | 0.66 | 0.48 | 1.30 | 5.93 | 105.72 | |||
| KNSA | 1.68 | 0.18 | 0.07 | 0.47 | 2.10 | 3.33 | 10.07 |
Cross Equities Net Income Analysis
Compare HUTCHMED DRC and related stocks such as Bausch Health Companies, Perrigo Company, and Ideaya Biosciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BHC | 3.9 M | 159.6 M | (116 M) | (866.1 M) | 881 M | (268.7 M) | (2.4 B) | 2.4 B | (4.1 B) | (1.8 B) | (559 M) | (948 M) | (225 M) | (592 M) | (46 M) | (41.4 M) | (43.5 M) |
| PRGO | 28.6 M | 401.6 M | 441.9 M | 205.3 M | 205.3 M | 127.9 M | (4 B) | 119.6 M | 131 M | 146.1 M | (162.6 M) | (68.9 M) | (140.6 M) | (12.7 M) | (171.8 M) | (154.6 M) | (146.9 M) |
| IDYA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (34.3 M) | (38.4 M) | (32.3 M) | (47.5 M) | (54.8 M) | (113 M) | (274.5 M) | (247 M) | (234.7 M) |
| SUPN | (17.3 M) | 56 M | (46.3 M) | (92.3 M) | 19.9 M | 14 M | 91.2 M | 57.3 M | 111 M | 113.1 M | 127 M | 53.4 M | 60.7 M | 1.3 M | 73.9 M | 84.9 M | 89.2 M |
| CPRX | (255.9 K) | (6.4 M) | (4.1 M) | (12.2 M) | (15.5 M) | (20.2 M) | (18.1 M) | (18.4 M) | (34 M) | 31.9 M | 75 M | 39.5 M | 83.1 M | 71.4 M | 163.9 M | 188.5 M | 197.9 M |
| SRRK | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (25 M) | (49.3 M) | (49.7 M) | (85 M) | (131.8 M) | (131.6 M) | (165.8 M) | (246.3 M) | (221.7 M) | (210.6 M) |
| ADPT | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (46.4 M) | (68.6 M) | (146.2 M) | (207.3 M) | (200.2 M) | (225.2 M) | (159.5 M) | (143.5 M) | (150.7 M) |
| MLYS | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (19.4 M) | (29.8 M) | (71.9 M) | (177.8 M) | (160 M) | (152 M) |
| CDTX | (792 K) | (792 K) | (792 K) | (1.3 M) | (11.9 M) | (32.2 M) | (48.2 M) | (55.7 M) | (59 M) | (41.1 M) | (72.1 M) | (43.9 M) | (29.8 M) | (22.9 M) | (169.8 M) | (152.8 M) | (145.2 M) |
| KNSA | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (64.9 M) | (103.2 M) | (161.9 M) | (161.4 M) | (157.9 M) | 183.4 M | 14.1 M | (43.2 M) | (49.7 M) | (52.2 M) |
HUTCHMED DRC and related stocks such as Bausch Health Companies, Perrigo Company, and Ideaya Biosciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in HUTCHMED DRC financial statement analysis. It represents the amount of money remaining after all of HUTCHMED DRC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.HUTCHMED DRC Competitive Analysis
The better you understand HUTCHMED DRC competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, HUTCHMED DRC's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across HUTCHMED DRC's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
HUTCHMED DRC Competition Performance Charts
Five steps to successful analysis of HUTCHMED DRC Competition
HUTCHMED DRC's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by HUTCHMED DRC in relation to its competition. HUTCHMED DRC's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of HUTCHMED DRC in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact HUTCHMED DRC's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to HUTCHMED DRC, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your HUTCHMED DRC position
In addition to having HUTCHMED DRC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Gambling Thematic Idea Now
Gambling
Companies that are related to providing gambling services across multiple geographical areas by investing, exploring, or producing software, hardware, and related infrastructure for running gambling operations or trading speculative assets. The Gambling theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gambling Theme or any other thematic opportunities.
| View All Next | Launch |
Check out HUTCHMED DRC Correlation with its peers. To learn how to invest in HUTCHMED Stock, please use our How to Invest in HUTCHMED DRC guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Will Pharmaceuticals sector continue expanding? Could HUTCHMED diversify its offerings? Factors like these will boost the valuation of HUTCHMED DRC. Market participants price HUTCHMED higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every HUTCHMED DRC data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 16.333 | Earnings Share 2.65 | Revenue Per Share | Quarterly Revenue Growth (0.09) | Return On Assets |
Understanding HUTCHMED DRC requires distinguishing between market price and book value, where the latter reflects HUTCHMED's accounting equity. The concept of intrinsic value—what HUTCHMED DRC's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push HUTCHMED DRC's price substantially above or below its fundamental value.
Please note, there is a significant difference between HUTCHMED DRC's value and its price as these two are different measures arrived at by different means. Investors typically determine if HUTCHMED DRC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, HUTCHMED DRC's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.